NCT06495281
Completed
Not Applicable
A Observational Study to Evaluate Effectiveness, Safety of Triple Combination Therapy of Zemidapa and Metformin in Patients With Type 2 DM Who Received Double or Triple Combination Therapy Including DPP4-inhibitor Other Than Gemigliptin
LG Chem1 site in 1 country2,044 target enrollmentOctober 26, 2023
ConditionsType 2 Diabetes Mellitus
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Type 2 Diabetes Mellitus
- Sponsor
- LG Chem
- Enrollment
- 2044
- Locations
- 1
- Primary Endpoint
- change from baseline of HbA1c at 12 weeks
- Status
- Completed
- Last Updated
- last month
Overview
Brief Summary
The aim of this study is to evaluate the effectiveness and safety of the triple combination therapy of Zemidapa Tab. and Metformin in patients with type 2 diabete mellitus
Investigators
Eligibility Criteria
Inclusion Criteria
- •type 2 DM Patients who are receiving one of the following three therapies during which the patients are prescribed with Zemidapa Tab. for the first time at the discretion of the attending physician:
- •Double combination therapy (Metformin and a DPP-4 inhibitor other than Gemigliptin)
- •Triple combination therapy (Metformin, a DPP-4 inhibitor other than Gemigliptin, and a SGLT-2 inhibitor)
- •Triple combination therapy (Metformin, a DPP-4 inhibitor other than Gemigliptin, and Sulfonylurea \[SU\])
- •patients with HbA1c results and who signed the written consent form
Exclusion Criteria
- •\- Patients contraindicated for the approved use of Zemidapa Tab. or have participated in another clinical study within 12 weeks
Outcomes
Primary Outcomes
change from baseline of HbA1c at 12 weeks
Time Frame: baseline, 12 weeks
Secondary Outcomes
- the rate of subjects who reached the target value of less than 7% HbA1c(12 weeks)
Study Sites (1)
Loading locations...
Similar Trials
Active, not recruiting
Phase 2
Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver FibrosisNASHNCT05327127Kowa Research Institute, Inc.228
Terminated
Phase 3
Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis CHepatitis CNCT01500772Debiopharm International SA6
Completed
Phase 3
Efficacy and Safety of AJU-A51 in Type 2 Diabetes Mellitus PatientsType2 DiabetesNCT06329674AJU Pharm Co., Ltd.235
Completed
Phase 3
Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular HypertensionGlaucoma, Open-AngleOcular HypertensionNCT01241240Allergan192
Completed
Phase 3
Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular HypertensionGlaucoma, Open-AngleOcular HypertensionNCT01217606Allergan185